Related Experiment Videos
Is tofisopam an atypical anxiolytic?
Neuroscience and Biobehavioral Reviews
|January 1, 1986
Summary
Tofisopam, a novel benzodiazepine, shows anxiolytic effects in humans without sedation. Its unique dopamine interactions may offer a new way to manage anxiety by improving coping skills, unlike traditional tranquilizers.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Tofisopam is a 3,4-benzodiazepine with a distinct profile from 1,4-benzodiazepines.
- Classical benzodiazepines (e.g., diazepam) exhibit anxiolytic, sedative, and muscle relaxant properties.
Purpose of the Study:
- To review the behavioral and biochemical characteristics of tofisopam.
- To explore the unique mechanisms of action and potential therapeutic applications of tofisopam.
- To compare tofisopam with buspirone, another novel anxiolytic.
Main Methods:
- Review of existing literature on tofisopam's behavioral and biochemical effects.
- Analysis of in vivo and in vitro animal studies.
- Comparison of tofisopam's effects with classical benzodiazepines and buspirone.
Main Results:
- Tofisopam demonstrates anxiolytic activity in humans without significant sedative or muscle relaxant side effects.
- In animal models sensitive to 1,4-benzodiazepines, tofisopam lacks anxiolytic and anticonvulsant properties.
- Tofisopam exhibits mixed dopamine agonist and antagonist properties in various animal tests.
Conclusions:
- Tofisopam's unique pharmacological profile, including its interaction with dopamine systems, differentiates it from classical benzodiazepines.
- Tofisopam and buspirone may represent a novel class of anxiolytics that enhance coping abilities rather than inducing tranquilization.
- Further research is warranted to elucidate the clinical relevance of tofisopam's dopamine-related effects.